- Home
- EVAX
EVAX
Evaxion Biotech A/S
as 07-26-2024 4:00pm EST
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.6M | IPO Year: | 2021 |
| Target Price: | $11.00 | AVG Volume (30 days): | 25.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.26 - $13.82 | Next Earning Date: | 08-15-2024 |
| Revenue: | $73,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 129.15% | Revenue Growth (next year): | -23.48% |
Latest Evaxion Biotech A/S News
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
GlobeNewswire
24 days ago
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
GlobeNewswire
a month ago
Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method
GlobeNewswire
a month ago
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
Zacks
a month ago
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare EVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVAX Evaxion Biotech A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.